Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision.

Biographies:
Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Georgia Cancer Center

Christopher J.D. Wallis is a Urology Resident at the University of Toronto. He obtained his Doctor of Medicine from the University of British Columbia and his Doctor of Philosophy in Clinical Epidemiology and Health Care Research from the Institute of Health Policy, Management, and Evaluation at the University of Toronto.

Related Content: 

First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer

Watch: IMAAGEN Trial: A Look into the Non-Metastatic Prostate Cancer Space - Charles Ryan

Cabazitaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer-FIRSTANA